Literature DB >> 17767025

[Hormone replacement Up-to-date. Effects of estrogen replacement therapy on lipid metabolism].

Akihiko Wakatsuki1.   

Abstract

Postmenopausal hormone replacement therapy (HRT) has favorable effects on lipids and decreases the risk of cardiovascular disease (CVD). Since Women's Health Initiative (WHI) has demonstrated that HRT increases the risk of CVD, indications of HRT use have been limited. Oral estrogen has several adverse effects on the risk of CVD. Oral estrogen increases the plasma triglyceride concentrations that decrease the size of LDL particles. Synthetic progestagens such as medroxyprogesterone acetate (MPA) decreases the plasma concentrations of high-density lipoprotein cholesterol. In contrast, recent studies demonstrated that transdermal estrogen or low dose oral estrogen administration, and the use of natural progestagen can protect against adverse effects of oral estrogen. Further studies are needed to investigate whether transdermal or low dose of estrogen administration and the use of natural progestagens can decrease the risk of CVD.

Entities:  

Mesh:

Year:  2007        PMID: 17767025     DOI: CliCa070913661371

Source DB:  PubMed          Journal:  Clin Calcium        ISSN: 0917-5857


  2 in total

1.  Tamoxifen use and potential effects on liver parenchyma: A long-term prospective transient elastographic evaluation.

Authors:  C Louwrens Braal; Robert J de Knegt; Agnes Jager; Stijn L W Koolen; Ron H J Mathijssen; Karel Eechoute
Journal:  Hepatol Commun       Date:  2022-06-10

2.  A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer.

Authors:  Ying Lin; Jianlun Liu; Xiaohua Zhang; Li Li; Rui Hu; Jian Liu; Yongchuan Deng; Dedian Chen; Yangbing Zhao; Shengrong Sun; Rong Ma; Ying Zhao; Jinping Liu; Yang Zhang; Xijing Wang; Yafen Li; Pingqing He; Enxiao Li; Zheli Xu; Yaqun Wu; Zhongsheng Tong; Xiaojia Wang; Tao Huang; Zhongxiao Liang; Shui Wang; Fengxi Su; Yunfei Lu; Helong Zhang; Guosheng Feng; Shenming Wang
Journal:  Cancer Sci       Date:  2014-09-18       Impact factor: 6.716

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.